**Supple 1.** Patient, disease, and response characteristics for +1q Standard Risk vs. +1q High Risk Characteristics

|  |  |  |  |
| --- | --- | --- | --- |
|  | **+1q Standard Risk N=88** | **+1q High Risk N=32** | ***p* value** |
| **Median age, years (range)** |   |   |   |
|   | At Diagnosis | 61 (21-77) | 62 (29-77) | 0.75 |
|   | At ASCT | 62 (26-78) | 63 (31-79) | 0.69 |
| **Age >65, n(%)** | 32 (36) | 14 (44) | 0.53 |
| **Sex, n (%)** |   |   |   |
|   | Male | 41 (47) | 16 (50) | 0.84 |
|   | Female | 47 (53) | 16 (50) |
| **Race/Ethnicity, n (%)** |   |   |   |
|   | Non-Hispanic White | 53 (60) | 21 (66) | 0.34 |
|   | Non-Hispanic Black | 35 (40) | 9 (28) |
| **Body Mass Index, n (%)** |   |   |   |
|   | <30 kg/m2 | 55 (63) | 16 (50) | 0.29 |
|   | ≥30 kg/m2 | 33 (38) | 16 (50) |
| **Subtype, n (%)** |   |   |   |
|   | IgG | 58 (66) | 16 (50) | 0.08 |
|   | IgA | 17 (19) | 14 (44) |
|   | Light chain only | 9 (10) | 2 (6) |
|   | Non-secretory | 2 (2) | 0 |
|   | Other | 2 (2) | 0 |
| **Durie-Salmon Staging System (DSS), n (%)** |   |   |   |
|   | I | 5 (6) | 3 (9) | 0.25 |
|   | II | 18 (20) | 3 (9) |
|   | III | 30 (34) | 16 (50) |
|   | Unknown | 35 (40) | 10 (31) |
| **International Staging System (ISS), n (%)** |   |   |   |
|   | I | 18 (20) | 1 (3) | 0.07 |
|   | II | 25 (28) | 8 (25) |
|   | III | 24 (27) | 10 (31) |
|   | Unknown | 21 (24) | 13 (41) |
| **Revised International Staging System (R-ISS), n (%)** |   |   |   |
|   | I | 10 (11) | 0 | 0.003 |
|   | II | 17 (19) | 6 (19) |
|   | III | 4 (5) | 8 (25) |
|   | Unknown | 57 (65) | 18 (56) |
| **ECOG performance status, n (%)** |   |   |   |
|   | 0 | 12 (14) | 5 (16) | 0.82 |
|   | 1 | 72 (82) | 25 (78) |
|   | 2+ | 3 (3) | 2 (6) |
|   | Missing | 1 (1) | 0 |
| **Cytogenetic abnormalities, n (%)** |   |   |   |
|   | Del 17p | 0 | 10 (31) | **<0.0001** |
|   | t4;14 | 0 | 19 (59) | **<0.0001** |
|   | t14;16 | 0 | 4 (13) | **0.004** |
|   | t14;20 | 1 (1) | 0 | 1.00 |
|   | Amp 1q | 0 | 1 (3) | 0.27 |
|   | Gain 1q | 88 (100) | 32 (100) | ND |
| **HCT-CI, n (%)** |   |   |   |
|   | 0-1 | 25 (38) | 8 (33) | 0.32 |
|   | 2-3 | 28 (43) | 8 (33) |
|   | 4+ | 12 (18) | 8 (33) |
| **sCr>2 or CrCl<60 mL/min/1.73 m2 at ASCT, n (%)** |   |   |   |
|   | Yes | 15 (17) | 6 (19) | 0.98 |
|   | No | 59 (67) | 21 (66) |
|   | Missing | 14 (16) | 5 (16) |
| **Melphalan dose, n (%)** |   |   |   |
|   | 200 mg/m2 | 67 (76) | 22 (69) | 0.48 |
|   | 140 mg/m2 | 21 (24) | 10 (31) |
| **Induction Regimen, n (%)** |   |   |   |
|   | RVd | 48 (55) | 15 (47) | **0.045** |
|   | Dara-RVd | 7 (8) | 4 (13) |
|   | CyBorD | 22 (25) | 4 (13) |
|   | Carfilzomib-based | 2 (2) | 5 (16) |
|   | Other | 9 (10) | 4 (13) |
| **Maintenance Regimen, n (%)** |   |   |   |
|   | Lenalidomide | 54 (61) | 17 (53) | 0.85 |
|   | Lenalidomide + PI | 17 (19) | 6 (19) |
|   | Lenalidomide + Daratumumab | 6 (7) | 3 (9) |
|   | PI only | 1 (1) | 0 |
|   | Other | 6 (7) | 3 (9) |
|   | None | 4 (5) | 3 (9) |
| **Best overall response post ASCT, n (%)** |   |   |   |
|   | sCR/CR | 35 (41) | 11 (37) | 0.055 |
|   | VGPR | 37 (43) | 16 (53) |
|   | PR | 13 (15) | 1 (3) |
|   | SD | 0 | 2 (7) |
|   | PD | 1 (1) | 0 |
| **Response prior to ASCT, n (%)** |   |   |   |
|   | sCR/CR | 16 (18) | 4 (13) | 0.22 |
|   | VGPR | 37 (43) | 10 (31) |
|   | PR | 30 (34) | 15 (47) |
|   | SD | 2 (2) | 3 (9) |
|   | PD | 2 (2) | 0 |
| **Response at Day+100 post ASCT, n (%)** |   |   |   |
|   | sCR/CR | 25 (29) | 9 (30) | 0.27 |
|   | VGPR | 43 (50) | 17 (57) |
|   | PR | 16 (19) | 2 (7) |
|   | SD | 0 | 1 (3) |
|   | PD | 2 (2) | 1 (3) |
| **Response at 2-year post ASCT, n (%)** |   |   |   |
|   | sCR/CR | 15 (32) | 3 (16) | 0.59 |
|   | VGPR | 10 (21) | 5 (26) |
|   | PR | 5 (11) | 1 (5) |
|   | SD | 2 (4) | 1 (5) |
|   | PD | 15 (32) | 9 (47) |